Posts Tagged ‘Biosimilars’
Discussion of the distinction between biosimilars and biologic originators and the cost and approval process of biosimilars for rheumatoid arthritis.
Little progress on FDA path of biosimilar biologics for RD It’s hard to believe it’s been almost two years since we’ve discussed biosimilars on Rheumatoid Arthritis Warrior (RAW). What’s even harder to believe: the situation in the U.S. is much the same: 1) The Biologics Price Competition and Innovation Act (BPCI) was created as a […]
The FDA definition of biosimilars and a pathway to approval Biosimilars are pharmaceuticals that are similar to biologics such as Enbrel and Humira, but not chemically identical as with generic drugs. If the unique molecules used to create a biologic (from living proteins) such as Enbrel are not cloned, but carefully imitated, they are considered […]